empty
 
 
nl
Search
Ondersteuning
Direct openen van een account
Trading Platform
Storting/opname
Search
Voor beginners Voor traders Voor partners Neem een ​​pauze About InstaSpot
nl
For Traders
Charts
#DVAX

#DVAX (Dynavax Technologies Corporation). Wisselkoers en online grafieken.

#DHR Terug naar de lijst met instrumenten #DXCM

Valuta converter

Dynavax Technologies Corporation
10.89 USD
09 Dec 2025 22:59
Prijsverandering (% chg)
$-0.02
(-0.18%)
Vorige close
Vorige close

Sluitprijs, de vorige dag.
$10.96
Open
Open

Openingsprijs.
$10.93
Hoog dag
Hoog dag

Hoogste prijs over vorige trading dag.
$11.12
Laag dag
Laag dag

De laagste prijs voor de laatste handelsdag
$10.85
52-wk Hoog
52-wk Hoog

Prijsklasse hoog in de laatste 52 weken
$11.28
52-wk Laag
52-wk Laag

Prijsklasse laag in de laatste 52 weken
$10.62
Download archief
Buy
10.89
Sell
10.89
Open the chart in full screen view
Buy
10.89
Sell
10.89
Download archief
Open the chart in full screen view

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

Kan u nu niet praten?
Stel uw vraag in de chat.